Research progress regarding the clinical evaluation on recombinant human papillomavirus vaccines

VernacularTitle:重组人乳头瘤病毒疫苗临床评价研究进展
Author: Wengang HE ¹ ; Jun ZHAO ; Shoujie HUANG ; Ting WU
Author Information

1. 361102,厦门大学公共卫生学院分子疫苗学和分子诊断学国家重点实验室国家传染病诊断试剂与疫苗工程技术研究中心
Keywords: Human papillomavirus; Vaccine; Clinical trials; Cervical cancer
From: Chinese Journal of Epidemiology 2016;37(6):904-908
CountryChina
Language:Chinese
Abstract: Human papillomavirus (HPV) is the main cause for cervical cancer,anogenital cancers and genital warts.Three HPV vaccines have been licensed abroad.Data from clinical trials showed high efficacy of the HPV vaccines in young women with 90％-100％ vaccine-related HPV diseases prevented.Though efficacy of the vaccine appears lower in older women,this population can still benefit from vaccination.Immunobriging trials show that the two-dose schedule in 9-14 years old girls elicits non-inferior immune response than the three-dose one in young adults.In addition,HPV vaccines can reduce the recurrent rates in CIN2 + patients after therapeutic surgery and the vaccines have cross-protection aganist diseases caused by non-vaccine type HPV.Safety data on HPV vaccines are assuring.Thus HPV vaccine should be widely used in adolescent girls and women of appropriate age groups.